The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships, Workshop Summary
Gavin Giovannoni, Ph.D., holds the Chair of Neurology in the Institute of Cell and Molecular Science, Queen Mary, University of London; the Department of Neurology, Barts; and The London NHS Trust, London. He did his undergraduate medical training at the University of the Witwaterstrand, South Africa. He moved to the Institute of Neurology, Queen Square, London, in 1993 after completing his specialist training in neurology. He was awarded a Ph.D. from the University of London in 1998. His special clinical interests are multiple sclerosis (MS) and other inflammatory disorders of the central nervous system (CNS). Specific research interests include MS-related neurodegeneration and MS biomarker discovery. He currently holds a program grant funded by the National MS Society and the MS Society of Great Britain and Northern Ireland to investigate novel neuroprotective and neurorestorative therapies in patients with MS. He runs an MS clinical trials unit and is chief investigator on several Phase II and III MS trials. He is particularly interested in optimizing MS disease-modifying therapies.
David Lewis, M.D., is UPMC Endowed Professor in Translational Neuroscience in the Departments of Psychiatry and Neuroscience at the University of Pittsburgh and director of the Translational Neuroscience Program at Western Psychiatric Institute and Clinic. He also serves as director of a National Institute of Mental Health (NIMH) Conte Center for the Neuroscience of Mental Disorders, which is focused on understanding the role of prefrontal cortical dysfunction in the pathophysiology of schizophrenia. He received his medical degree from The Ohio State University, completed residencies in internal medicine and psychiatry at the University of Iowa, and received his research training at the Research Institute of the Scripps Clinic. Dr. Lewis has published over 250 scientific articles. He is currently the recipient of an NIMH MERIT Award, and he serves on the Scientific Council for NARSAD. In addition, he is deputy editor of The American Journal of Psychiatry and section editor of clinical neuroscience for Neuroscience. Recognition of Dr. Lewis’s research accomplishments has included the NARSAD Lieber Prize for Schizophrenia Research, the Stanley Dean Research Award from the American College of Psychiatrists, and the American Psychiatric Association Kempf Award for Research Development.
Husseini K. Manji, M.D., is chief, Laboratory of Molecular Pathophysiology, NIMH, and director of the NIMH Mood and Anxiety Disorders Program, the largest program of its kind in the world. He is also a